Experience with glipasol (R. P. 2259)-an antidiabetic sulfonamide drug.
作者信息
DAVIS T W, KERR R B, BOGOCH A
出版信息
Can Med Assoc J. 1959 Jul 15;81(2):101-7.
Abstract
摘要
相似文献
1
Experience with glipasol (R. P. 2259)-an antidiabetic sulfonamide drug.
Can Med Assoc J. 1959 Jul 15;81(2):101-7.
2
Hepatitis caused by glipasol (R.P. 2259)--an antidiabetic sulphonamide drug.
Can Med Assoc J. 1960 Jul 16;83(3):102-12.
3
[Three-week treatment with antidiabetic sulfonamides causing prolonged amelioration in a diabetic].
Tip Fak Mecm. 1958;21(1):118-26.
4
[Toxicity and hypoglycemic activity of a recent antidiabetic sulfonamide].
Boll Soc Ital Biol Sper. 1960 Jan 31;36:47-8.
5
[A new oral antidiabetic: N,N-dimethylbiguanide. Therapeutic trials alternated with a placebo and a sulfonamide].
Acta Clin Belg. 1961;16:575-89.
6
[Clinical trials of a new antidiabetic sulfonamide: phenbutamide].
Lyon Med. 1960 Mar 20;92:789-808.
7
[Influence of some sulfonamide antidiabetic agents on the growth and fattening of swine].
Stud Cercet Endocrinol. 1962;13:815-7.
8
[Mechanism of action of hypoglycemic sulfonamide derivatives].
Rev Clin Esp. 1957 Sep 15;66(5):303-5.
9
[Clinical study of a new hypoglycemic sulfonamide: glyhexylamide].
Alger Medicale. 1961 Mar;65:219-27.
10
[HOW SHOULD THE ANTIDIABETIC SULFONAMIDES BE HANDLED?].
Presse Med (1893). 1963 Nov 2;71:2207-8.
引用本文的文献
1
Ipso-hydroxylation and subsequent fragmentation: a novel microbial strategy to eliminate sulfonamide antibiotics.
Appl Environ Microbiol. 2013 Sep;79(18):5550-8. doi: 10.1128/AEM.00911-13. Epub 2013 Jul 8.
2
Preliminary observations on management of diabetes with "stabinol".
Br Med J. 1960 Sep 24;2(5203):913-5. doi: 10.1136/bmj.2.5203.913.
3
Hepatitis caused by glipasol (R.P. 2259)--an antidiabetic sulphonamide drug.
Can Med Assoc J. 1960 Jul 16;83(3):102-12.
4
The clinical response and the amount of insulin extractable from the pancreas in diabetic patients treated with oral hypoglycaemic drugs: a report on five cases.
Can Med Assoc J. 1959 Sep 1;81(5):347-56.
本文引用的文献
1
A CONVENIENT METHOD FOR DETERMINING SERUM AND BILE PHOSPHATASE ACTIVITY.
Can Med Assoc J. 1934 Oct;31(4):376-81.
2
SEROLOGICAL DIFFERENTIATION OF OBSTRUCTIVE FROM HEPATOGENOUS JAUNDICE BY FLOCCULATION OF CEPHALIN-CHOLESTEROL EMULSIONS.
J Clin Invest. 1939 May;18(3):261-9. doi: 10.1172/JCI101042.
3
Experience with the tolbutamide treatment of five hundred cases of diabetes on an ambulatory basis.
Ann N Y Acad Sci. 1957 Jul 10;71(1):275-9.
4
Further experience with the use of sulfonylureas in diabetes.
Ann N Y Acad Sci. 1957 Jul 10;71(1):264-7.
5
Use of the sulfonylureas in diabetes mellitus.
Ann N Y Acad Sci. 1957 Jul 10;71(1):256-63.
6
Clinical experience with sulfonylurea compounds in diabetes.
Ann N Y Acad Sci. 1957 Jul 10;71(1):239-48.
7
Reports on studies with carbutamide and tolbutamide done at the Charles H. Best Institute, University of Toronto.
Ann N Y Acad Sci. 1957 Jul 10;71(1):164-9.
8
The hypoglycemic sulfonamides: history and development of the problem from 1942 to 1955.
Ann N Y Acad Sci. 1957 Jul 10;71(1):4-11. doi: 10.1111/j.1749-6632.1957.tb54569.x.
9
The toxic effect of carbutamide (BZ 55) in diabetic dogs.
Diabetes. 1957 Mar-Apr;6(2):151-3. doi: 10.2337/diab.6.2.151.
10
On the action of BZ-55 and D-860 in pancreatectomized dogs.
Diabetes. 1957 Mar-Apr;6(2):146-50. doi: 10.2337/diab.6.2.146.
Zotero 插件